April 27 Quick Takes: Avalyn raises $35M for fibrosis therapies, plus Actym, LifeSprout, HebeCell, Compass, Immunomic

Fibrosis company Avalyn raises $35.5M series B
Seattle’s Avalyn Pharma Inc. closed a $35.5 million B round, adding to its $62 million series A in 2017. The round was led by Norwest Venture Partners with participation from new investor Pivotal bioVenture Partners and existing investors F-Prime Capital Partners, Novo

Read the full 480 word article

How to gain access

Continue reading with a
two-week free trial.